

USPTO PATENT FULL-TEXT AND IMAGE DATABASE[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Bottom](#)[View Cart](#)

No/517,874

Searching US Patent Collection...

Results of Search in US Patent Collection db for:**(AN/Novartis AND fluvastatin): 7 patents.****Hits 1 through 7 out of 7**[Jump To](#)[Refine Search](#)

an/Novartis and fluvastatin

PAT. NO.	Title
1 6,992,105	Dipeptide derivatives
2 6,909,003	Process for the manufacture of organic compounds
3 6,869,970	Crystalline salt forms of valsartan
4 6,818,638	Melvinolin derivatives
5 6,777,443	Dipeptide derivatives
6 6,432,447	Organic compounds
7 6,242,003	Organic compounds

[Top](#)[View Cart](#)[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

Home	Quick	Advanced	Pat Num	Help
Next List		Bottom	View Cart	

Searching US Patent Collection...

Results of Search in US Patent Collection db for:

ACLM/(salt AND fluvastatin): 98 patents.

Hits 1 through 50 out of 98

[Next 50 Hits](#)


[Jump To](#)

[Refine Search](#)

PAT. NO.	Title
1 7,056,906	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
2 7,053,106	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
3 7,026,316	Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
4 7,019,010	Combinations
5 7,015,208	C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
6 6,995,180	Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods
7 6,982,251	Substituted 2-azetidinones useful as hypocholesterolemic agents
8 6,967,212	Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
9 6,936,590	C-aryl glucoside SGLT2 inhibitors and method
10 6,932,983	Porous drug matrices and methods of manufacture thereof
11 6,923,988	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
12 6,916,813	(1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
13 6,911,472	Pharmaceutical composition comprising a hmg-coa reductase inhibitor
14 6,897,198	Method of treatment with combinations of statin and aryl-substituted propanolamine derivatives
15 6,881,860	Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality

- 16 [6,875,782](#) [TI](#) [Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method](#)
- 17 [6,869,970](#) [TI](#) [Crystalline salt forms of valsartan](#)
- 18 [6,849,636](#) [TI](#) [Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1](#)
- 19 [6,838,566](#) [TI](#) [Salts of HMG-CoA reductase inhibitors](#)
- 20 [6,831,105](#) [TI](#) [Compositions comprising ether compounds and pharmaceutical uses therefor](#)
- 21 [6,811,786](#) [TI](#) [Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions](#)
- 22 [6,806,290](#) [TI](#) [Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same](#)
- 23 [6,800,605](#) [TI](#) [Aniline-derived ligands for the thyroid receptor](#)
- 24 [6,777,552](#) [TI](#) [Processes for preparing calcium salt forms of statins](#)
- 25 [6,730,690](#) [TI](#) [11-.beta.-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia](#)
- 26 [6,720,351](#) [TI](#) [Triamide-substituted heterobicyclic compounds](#)
- 27 [6,713,508](#) [TI](#) [Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders](#)
- 28 [6,696,479](#) [TI](#) [Crystalline forms](#)
- 29 [6,695,969](#) [TI](#) [Process for obtaining HMG-CoA reductase inhibitors of high purity](#)
- 30 [6,683,056](#) [TI](#) [O-aryl glucoside SGLT2 inhibitors and method](#)
- 31 [6,673,831](#) [TI](#) [Combination therapy for reducing the risks associated with cardiovascular disease](#)
- 32 [6,673,815](#) [TI](#) [Substituted acid derivatives useful as antidiabetic and antiobesity agents and method](#)
- 33 [6,660,300](#) [TI](#) [Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method](#)
- 34 [6,645,997](#) [TI](#) [Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders](#)
- 35 [6,645,974](#) [TI](#) [Androgen receptor modulators and methods for use thereof](#)
- 36 [6,586,448](#) [TI](#) [4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines](#)
- 37 [6,583,295](#) [TI](#) [Salts of HMG-CoA reductase inhibitors](#)
- 38 [6,569,879](#) [TI](#) [Aryloxyacetic acids for diabetes and lipid disorders](#)
- 39 [6,569,835](#) [TI](#) [Combinations with statin and aryl-substituted propanolamine derivatives, their preparation pharmaceuticals comprising them, and their use](#)
- 40 [6,569,463](#) [TI](#) [Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions](#)
- 41 [6,555,519](#) [TI](#) [O-glucosylated benzamide SGLT2 inhibitors and method](#)
- 42 [6,552,048](#) [TI](#) [Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals](#)
- 43 [6,548,529](#) [TI](#) [Heterocyclic containing biphenyl aP2 inhibitors and method](#)
- 44 [6,531,507](#) [TI](#) [Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same](#)
- 45 [6,525,083](#) [TI](#) [N-substituted indoles useful in the treatment of diabetes](#)
- 46 [6,515,117](#) [TI](#) [C-aryl glucoside SGLT2 inhibitors and method](#)
- 47 [6,489,478](#) [TI](#) [4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines](#)
- 48 [6,486,142](#) [TI](#) [Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B \(PTP-1B\)](#)
- 49 [6,486,141](#) [TI](#) [Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B](#)

(PTP-1B)















50 6,475,521  Biphasic controlled release delivery system for high solubility pharmaceuticals and method

[Next List](#)[Top](#)[View Cart](#)[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)

USPTO PATENT FULL-TEXT AND IMAGE DATABASE[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Bottom](#)[View Cart](#)*Searching US Patent Collection...***Results of Search in US Patent Collection db for:****(IN/Chen AND fluvastatin): 33 patents.***Hits 1 through 33 out of 33*[Jump To](#) [Refine Search](#)

PAT. NO.	Title
1 7,053,106	T Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
2 7,045,527	T Piperidine derivatives
3 6,995,181	T Modulators of the glucocorticoid receptor and method
4 6,982,281	T Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
5 6,933,291	T Cholesterol lowering supplement
6 6,923,988	T Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
7 6,919,358	T Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
8 6,916,812	T Alpha-aminoamide derivatives as melanocortin agonists
9 6,916,809	T Heterocyclic acridone inhibitors of IMPDH enzyme
10 6,902,902	T Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
11 6,875,782	T Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
12 6,812,345	T HMG-CoA reductase inhibitors and method
13 6,761,903	T Clear oil-containing pharmaceutical compositions containing a therapeutic agent
14 6,750,213	T Estrogen receptor modulators
15 6,727,271	T Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
16 6,720,001	T Emulsion compositions for polyfunctional active ingredients
17 6,653,314	T Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
18 6,596,760	T Antidiabetic 4-hydroxy-2-furoic acids
19 6,569,463	T Solid carriers for improved delivery of hydrophobic active ingredients in

pharmaceutical compositions

- 20 6,525,067  Substituted heterocyclic derivatives
- 21 6,485,748  Once daily pharmaceutical tablet having a unitary core
- 22 6,451,339  Compositions and methods for improved delivery of hydrophobic agents
- 23 6,432,989  Use of CRF antagonists to treat circadian rhythm disorders
- 24 6,414,002  Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
- 25 6,383,471  Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
- 26 6,294,192  Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
- 27 6,267,985  Clear oil-containing pharmaceutical compositions
- 28 6,248,363  Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
- 29 5,837,379  Once daily pharmaceutical tablet having a unitary core
- 30 5,468,771  Cholesterol lowering compound
- 31 5,359,096  Cholesterol lowering compounds
- 32 5,302,604  Cholesterol lowering compounds produced by directed biosynthesis
- 33 5,294,627  Directed biosynthesis of biologically active compounds
-

[Top](#)[View Cart](#)[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)